Publication | Open Access
1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY
34
Citations
0
References
2013
Year
Or 16Command Gt2/3 StudyHepatitis CViral HepatitisAntiviral TherapyHepatitisVirologyInfection ControlAntiviral DrugMedicineOr 3
No additional data available for this publication yet. Check back later!